the total number of rare disease patients in China has reached approximately 20 million, with a growth rate exceeding 200,000 new patients per year. Given China's 1.4 billion population, many rare diseases in China are no longer “rare” compared to other countries and regions.[1]For a long...
Huang Rufang, the founder of CORD, said that the list is one of the most important policies carried out in the development of rare diseases in China. “I am so delighted as a rare disease patient myself to see such a great leap made in this industry under concerted efforts,” Huang sai...
Drugs in the2018 National Essential Drug List. Drugs in theEncouraged Generic Drug List/List of Pediatric Drugs Encouraged for R&D and Applicationand approved by NMPA before June 30, 2022. Rare disease drugs (orphan drugs) approved by NMPA before...
With over 150 drugs now approved for upwards of 90 different rare diseases in China, including 80 molecules covered by the National Reimbursement Drug List (NRDL), this report provides a catch-up on recent policy support and market conditions for orphan disease developers in the China market....
Y Cui,J Han - 《Intractable & Rare Diseases Research》 被引量: 3发表: 2017年 Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022 actively working on improving orphan drug accessibility in the past decades, especially since 2018 when the First National List of ...
The new entries into the catalog cover 16 types of rare disease, which means a total of 80 orphan drugs now feature on the medical insurance list, including drugs needed for the treatment of myasthenia gravis and atypical hemolytic uraemic syndrome. ...
China rare disease drugs clinical pharmacology research technical guidelines have been drafted for comments by the CDE on October 12, 2024.
A letter to the editor is presented which discusses rare disease research and data collection in China, including in regard to pilot project known as the Ministry of Science and Technology of China Grants, clinical data and the collecting of bio-specimens from pediatric patients....
Topic:UK-China Partnership in Tackling Rare Disease Challenges Globally 中英携手应对罕见病领域的挑战 Moderator 主持人: Linguo, LI, Senior Researcher, Public Policy Research Centre of Rare Diseases, CORD 李林国,蔻德罕见病中心(CORD)公共政策研究中心项目负责人 ...
Seven rare-disease medicines were included in the country's medicare reimbursement list in 2021, with an average price reduction of 65 percent. (Xinhua/Guo Xulei) A medical worker injects Spinraza to a 4-year-old child diagnosed with spinal muscular atrophy (SMA) at a hospital in Zaozhuang,...